Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Revenue (2021 - 2025)

Historic Revenue for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $14.3 million.

  • Verrica Pharmaceuticals' Revenue rose 70539.02% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year increase of 14137.96%. This contributed to the annual value of $7.6 million for FY2024, which is 4765.81% up from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Revenue stood at $14.3 million for Q3 2025, which was up 70539.02% from $12.7 million recorded in Q2 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' Revenue peaked at $14.3 million during Q3 2025, and registered a low of $37000.0 during Q1 2023.
  • Over the past 5 years, Verrica Pharmaceuticals' median Revenue value was $2.5 million (recorded in 2023), while the average stood at $4.2 million.
  • In the last 5 years, Verrica Pharmaceuticals' Revenue crashed by 9640.83% in 2022 and then surged by 1024054.05% in 2024.
  • Verrica Pharmaceuticals' Revenue (Quarter) stood at $12.0 million in 2021, then crashed by 99.43% to $68000.0 in 2022, then soared by 2823.53% to $2.0 million in 2023, then tumbled by 82.7% to $344000.0 in 2024, then skyrocketed by 4069.77% to $14.3 million in 2025.
  • Its Revenue was $14.3 million in Q3 2025, compared to $12.7 million in Q2 2025 and $3.4 million in Q1 2025.